Completed PHASE3 INTERVENTIONAL NCT00180050

Budesonide Treatment for Lymphocytic Colitis

Efficacy and Safety of Budesonide for Treatment of Lymphocytic Colitis

Sponsor: Dr. Falk Pharma GmbH

Interventions Budesonide

Updated 5 times since 2017 Last updated: Mar 29, 2010 Started: Jan 31, 2002 Primary completion: Aug 31, 2006 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00180050, this PHASE3 trial focuses on Microscopic Colitis and remains completed. Sponsored by Dr. Falk Pharma GmbH, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Falk Pharma GmbH
Technische Universität Dresden

Data source: Technische Universität Dresden

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dresden, Germany